Higher mortality in patients with milder autonomous cortisol secretion

Background Current evidence highlights the need for appropriate diagnosis and therapy to improve outcomes in people with mild autonomous cortisol secretion (MACS). We aimed to validate the clinical sex-specific significance of the novel diagnosis MACS by characterizing patients according to morbidity and mortality in a real-world setting. Methods This retrospective single-center cohort study included clinical data from 670 adult patients with adrenal adenomas undergoing diagnostic workup regarding adrenal hypercortisolism at the Vienna General Hospital from 01.01.2000 to 31.12.2022. For mortality analyses, follow-up data spanning over 20 years was available, patients alive after 01.12.2024 were censored. Patients were classified into 3 groups based on post 1mg-DST cortisol levels (≤1.8µg/dL (suppressed 1mg-DST); >1.8 to ≤5µg/dl (mildly elevated 1mg-DST); >5µg/dL (markedly elevated 1mg-DST)) and analyzed according to cortisol-associated morbidity and mortality. Results Compared to those with suppressed 1mg-DST, patients with mildly elevated 1mg-DST were more frequently diagnosed with cortisol-associated diseases like cardiovascular disease (CVD) and osteoporosis while patients with markedly elevated 1mg-DST had more frequently arterial hypertension (aHTN) and osteoporosis, particularly women. Patients with mildly elevated 1mg-DST exhibited the highest mortality, despite comparable prevalence rates of cortisol-associated comorbidities between the mildly and the markedly elevated 1mg-DST group, even after adjusting for age, sex, BMI and cardiometabolic risk factors (HR 1.57 ( 95% CI: 1.01-2.45)). This was attenuated after additional adjustment for cancer history. Conclusion We identified the mildly elevated 1mg-DSTgroup as a high-risk formerly overlooked cohort, characterized by increased morbidity and mortality. Further prospective studies are needed to clarify the underlying mechanisms and the potential role of cortisol-specific treatment.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-16
DOI
https://doi.org/10.3389/fendo.2026.1913679
Primary Topic
Adrenal and Paraganglionic Tumors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Higher mortality in patients with milder autonomous cortisol secretion

Sarah Hofer-Zeni, Dorota Sluková, Greisa Vila, Luise Bellach et al.
2 links
Frontiers in Endocrinology
Adrenal and Paraganglionic Tumors
article

Higher mortality in patients with milder autonomous cortisol secretion

Sarah Hofer-Zeni, Dorota Sluková, Greisa Vila, Luise Bellach, Michael Leutner, Alexandra Kautzky‐Willer, Peter Wolf, Rodrig Marculescu, Dorothea Kalender, Liliana Gard, Sabina Baumgartner-Parzer
article en

Abstract

Background Current evidence highlights the need for appropriate diagnosis and therapy to improve outcomes in people with mild autonomous cortisol secretion (MACS). We aimed to validate the clinical sex-specific significance of the novel diagnosis MACS by characterizing patients according to morbidity and mortality in a real-world setting. Methods This retrospective single-center cohort study included clinical data from 670 adult patients with adrenal adenomas undergoing diagnostic workup regarding adrenal hypercortisolism at the Vienna General Hospital from 01.01.2000 to 31.12.2022. For mortality analyses, follow-up data spanning over 20 years was available, patients alive after 01.12.2024 were censored. Patients were classified into 3 groups based on post 1mg-DST cortisol levels (≤1.8µg/dL (suppressed 1mg-DST); >1.8 to ≤5µg/dl (mildly elevated 1mg-DST); >5µg/dL (markedly elevated 1mg-DST)) and analyzed according to cortisol-associated morbidity and mortality. Results Compared to those with suppressed 1mg-DST, patients with mildly elevated 1mg-DST were more frequently diagnosed with cortisol-associated diseases like cardiovascular disease (CVD) and osteoporosis while patients with markedly elevated 1mg-DST had more frequently arterial hypertension (aHTN) and osteoporosis, particularly women. Patients with mildly elevated 1mg-DST exhibited the highest mortality, despite comparable prevalence rates of cortisol-associated comorbidities between the mildly and the markedly elevated 1mg-DST group, even after adjusting for age, sex, BMI and cardiometabolic risk factors (HR 1.57 ( 95% CI: 1.01-2.45)). This was attenuated after additional adjustment for cancer history. Conclusion We identified the mildly elevated 1mg-DSTgroup as a high-risk formerly overlooked cohort, characterized by increased morbidity and mortality. Further prospective studies are needed to clarify the underlying mechanisms and the potential role of cortisol-specific treatment.

Frontiers in EndocrinologyVol. 17
Medical University of Vienna (AT)
Good health and well-being
Adrenal and Paraganglionic Tumors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon